Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | F12 | P00748 | 1/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282759 | 0.89 | PLAU (0.44) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL9112308 | 0.87 | PLAU (0.43) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL291937 | 0.84 | PLAU (0.50) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL29986248 | 0.84 | PLAU (0.50) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL3248709 | 0.84 | PLAU (0.50) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL3250398 | 0.84 | PLAU (0.50) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL18154032 | 0.82 | PLAU (0.48) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL31122674 | 0.82 | PLAU (0.48) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL2307025 | 0.81 | PLAU (0.52) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL1574566 | 0.81 | PLAU (0.47) | PLAUCYP2A6F12NCF1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164849-A2 | PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | AEterna Zentaris GmbH (DE) | 2010-03-24 | — | — | EP | claimed |
| WO-2008138878-A2 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | ÆTERNA ZENTARIS GMBH (DE) | 2008-11-20 | — | — | WO | claimed |
| EP-2212328-B1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF | CHOONGWAE PHARMA CORP (KR) | 2017-01-25 | — | — | EP | disclosed |
| CN-103539797-B | Compounds of reverse turn mimetics and uses thereof | JW PHARMACEUTICAL CORPORATION (KR) | 2016-05-18 | — | — | CN | disclosed |
| EP-2212330-B1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (3) | CHOONGWAE PHARMA CORP (KR) | 2015-04-08 | — | — | EP | disclosed |
| EP-2212329-B1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (1) | CHOONGWAE PHARMA CORP (KR) | 2014-07-30 | — | — | EP | disclosed |
| CN-101827850-B | Novel compounds of reverse turn mimetics and use thereof (2) | CHOONGWAE PHARM CO | 2014-03-12 | — | — | CN | disclosed |
| CN-103539797-A | Novel compounds of reverse turn mimetics and the use thereof | JW PHARMACEUTICAL CORP | 2014-01-29 | — | — | CN | disclosed |
| CN-101827849-B | Novel compounds of reverse turn mimetics and uses thereof | CHOONGWAE PHARMA CORP | 2013-07-24 | — | — | CN | disclosed |
| US-8138337-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-03-20 | — | — | US | disclosed |
| US-8080657-B2 | Compounds of reverse turn mimetics and the use thereof | CHOONGWAE PHARMA CORPORATION (KR) | 2011-12-20 | — | — | US | disclosed |
| EP-1718309-A2 | ANORECTIC COMPOUNDS | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005072740-A2 | ANORECTIC COMPOUNDS | JAPAN TOBACCO INC. (JP) | 2005-08-11 | — | — | WO | disclosed |
| US-20040127433-A1 | excellent antibacterial activity especially against a typical acid-fast mycobacteria including multiple drug-resistant bacteria | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1323726-A1 | ERYTHROMYCIN DERIVATIVES AND MEDICINES CONTAINING THE SAME | HOKURIKU SEIYAKU CO., LTD. (JP) | 2003-07-02 | — | — | EP | disclosed |
| EP-1167375-A1 | ERYTHROMYCIN DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-5616586-A | Tricyclic quinoxalinediones | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1997-04-01 | — | — | US | disclosed |
| WO-1996040141-A1 | 4,5-BRIDGED QUINOXALINEDIONES AND QUINOLONES AND THE USE THEREOF AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ACEA PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0642508-A1 | TRICYCLIC QUINOXALINEDIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1995-03-15 | — | — | EP | disclosed |
| WO-1993008188-A1 | TRICYCLIC QUINOXALINEDIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127433-A1 | excellent antibacterial activity especially against a typical acid-fast mycobacteria including multiple drug-resistant bacteria | MAPRE1, MAPRE2, MRPS27 | PLAU 4592/4885CYP2A6 1920/4885F12 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.